OncLive TV

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.

David L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.

Lori A. Leslie, MD, discusses the 3-year follow-up data of the phase 2 ZUMA-5 trial in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.

Carlo Contreras, MD, discusses areas of planned and ongoing research with neoadjuvant therapies in basal cell carcinoma and cutaneous squamous cell carcinoma.

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Chan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.

Charu Aggarwal, MD, MPH, discusses treating patients with EGFR-mutant non­–small cell lung cancer.

Daniel J. George, MD, discusses the clinical benefits of evaluating phenotype in metastatic castration-resistant prostate cancer.

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Jorge M. Mercado, MD, discusses the effect of the COVID-19 pandemic on lung cancer screening.

Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.

Daniel J. George, MD, discusses the importance of understanding mutations in prostate cancer.

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.

Regis Peffault de Latour, MD, PhD, discusses the benefit observed with iptacopan vs standard-of-care eculizumab or ravulizumab in patients with paroxysmal nocturnal hemoglobinuria and residual anemia during the phase 3 APPLY-PNH trial.

Max S. Topp, MD, discusses the efficacy of the combination of glofitamab plus R-CHOP from a phase 1 trial done in previously untreated patients with diffuse large B-cell lymphoma.

Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Jeremy Abramson, MD, discusses the efficacy data of second-line lisocabtagene maraleucel vs standard-of-care salvage chemotherapy followed by autologous stem cell transplant from the phase 3 TRANSFORM trial done in patients with relapsed/refractory large B-cell lymphoma.

Ajay Chari, MD, discusses findings from the phase 1/2 MonumenTAL-1 trial investigating talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

Jesus G. Berdeja, MD, discusses the investigation of BMS-986393 in patients with relapsed/refractory multiple myeloma.

Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Claire F. Verschraegen, MD, discusses the need to improve the management of treatment-related adverse effects of immunotherapy in melanoma.

Daniel J. George, MD, discusses the use of niraparib for patients with metastatic castration-resistant prostate cancer harboring BRCA and ATM mutations.

Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.